I first met Eric von Hofe in 2008 at the Rodman &
Post# of 36563
(Total Views: 731)
Posted On: 10/16/2021 12:28:09 AM
I first met Eric von Hofe in 2008 at the Rodman & Renshaw 10th Annual Healthcare Conference in New York City. I walked into various biotech company presentation rooms, but specifically went to see the Generex presentation. Anna Gluskin was listed to present, but was unavailable so Eric made the trip from near Boston to give a comprehensive overview of Generex and Antigen Express. And after his session, I met with him privately one on one outside the public room and immediately thought Generex should push him up to CEO for professional and intellectual credibility reasons. No offense to Anna, but Generex never understood that real biotech investors want INDs, clinical studies, peer reviews, new patents, professionalism and not sugar sprays, Ecuador, acquisition of mail in order supply “Medicare” nonsense companies or anything nonsensical that takes funds from science.
Can you imagine if Generex stopped sending press releases to “A-Rod” about the ridiculous Glucose RapidSpray or wasting funds plus dilutive shares for the fake marriage with a make believe company like Amarantus and instead was steadfast in advancing solely AE37 and Ii-key (lrmk)?
And in newer times, with great respect to Joe, as Monday morning quarterbacking is easy, I’d extremely prefer a science first approach thet is always and ONLY strictly needed- not “high risk” “low reward” headlines for extremely dilutive acquisition targets for a weak Emmaus Life Science or the wildly toxic Veneto. If it were up to me, I’d never chase anything in Arizona or even have a discussion with someone like Terry Thompson. Not happening. Only AE37 is happening. Multiple studies could’ve occurred per my opinion. Anything else ONLY occurs once strong footing occurs for my stock, my shareholders, and a “goal” to become a holding company. And that, far from now once on a National exchange or if that’s even deemed wise, only makes sense while conservatively targeting clean intellectually strong companies. I’d pass on Olaregen. Focus!
I’m not saying that to give Joe a hard time. I feel he did an outstanding job in bringing the Ii-Key Covid vaccine so far. It’s just my opinion on all the other things with Terry or Sanjay, because after a massive reverse split, with comparatively very modest dividends, the stock keeps getting too diluted as focus is too far spread during a historic pandemic. And it may turn out to be super smart and effective. It hasn’t been.
Anyway, my point was about Eric. He is still highly involved with NGIO (Antigen Express), but as I’ve noted a few times he’s the CEO of another life science company. I’m liking their science focus approach. I don’t think they’re public yet, but they’ve successfully published peer reviews, filed INDs, raised an additional $30 million in funds, all to move forward in the clinic. This is what we want to see for NuGenerex Immuno. Not weird acquisitions. Advance science, conserve funds and shares only for that. Be real and value grows, imho:
https://www.onclive.com/view/fda-grants-fast-...oid-cancer
https://endpts.com/tiny-player-picks-up-30m-t...hallenges/
https://www.genetherapylive.com/view/reducing...-therapies
Can you imagine if Generex stopped sending press releases to “A-Rod” about the ridiculous Glucose RapidSpray or wasting funds plus dilutive shares for the fake marriage with a make believe company like Amarantus and instead was steadfast in advancing solely AE37 and Ii-key (lrmk)?
And in newer times, with great respect to Joe, as Monday morning quarterbacking is easy, I’d extremely prefer a science first approach thet is always and ONLY strictly needed- not “high risk” “low reward” headlines for extremely dilutive acquisition targets for a weak Emmaus Life Science or the wildly toxic Veneto. If it were up to me, I’d never chase anything in Arizona or even have a discussion with someone like Terry Thompson. Not happening. Only AE37 is happening. Multiple studies could’ve occurred per my opinion. Anything else ONLY occurs once strong footing occurs for my stock, my shareholders, and a “goal” to become a holding company. And that, far from now once on a National exchange or if that’s even deemed wise, only makes sense while conservatively targeting clean intellectually strong companies. I’d pass on Olaregen. Focus!
I’m not saying that to give Joe a hard time. I feel he did an outstanding job in bringing the Ii-Key Covid vaccine so far. It’s just my opinion on all the other things with Terry or Sanjay, because after a massive reverse split, with comparatively very modest dividends, the stock keeps getting too diluted as focus is too far spread during a historic pandemic. And it may turn out to be super smart and effective. It hasn’t been.
Anyway, my point was about Eric. He is still highly involved with NGIO (Antigen Express), but as I’ve noted a few times he’s the CEO of another life science company. I’m liking their science focus approach. I don’t think they’re public yet, but they’ve successfully published peer reviews, filed INDs, raised an additional $30 million in funds, all to move forward in the clinic. This is what we want to see for NuGenerex Immuno. Not weird acquisitions. Advance science, conserve funds and shares only for that. Be real and value grows, imho:
https://www.onclive.com/view/fda-grants-fast-...oid-cancer
https://endpts.com/tiny-player-picks-up-30m-t...hallenges/
https://www.genetherapylive.com/view/reducing...-therapies
(8)
(0)